Krensavage Asset Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 15, 2024), Krensavage Asset Management, LLC reported 13 stock positions worth $178.5 million. Its top holding was United Therapeutics (UTHR) at 20.1% of the portfolio, followed by Exelixis (EXEL, 18.6%) and Cardinal Health (CAH, 13.0%). Compared with Q2 2024, it opened 1 new position, sold out of 1, added to 3 and reduced 9. The biggest buy was a new position in Indivior (INDV) and the biggest sale an exit from Taro Pharmaceutical Indus (TARO).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001609251
- Portfolio Value
- $178.5M (Q3 2024)
- SEC Filing
- 0001642274-24-000006 ↗ filed Nov 15, 2024
Holdings Value
Holdings 13 stocks · $178.5M
| UTHR United Therapeutics Corp. | 20.15% | 100,332 | $36.0M | Reduce -15.1% |
| EXEL Exelixis Inc. | 18.64% | 1,281,612 | $33.3M | Reduce -23.6% |
| CAH Cardinal Health Inc. | 13.02% | 210,263 | $23.2M | Reduce -3.4% |
| BIIB Biogen Inc. | 12.33% | 113,502 | $22.0M | Reduce -8.3% |
| ENTA Enanta Pharmaceuticals Inc. | 8.70% | 1,498,074 | $15.5M | Add +19.7% |
| JAZZ Jazz Pharmaceuticals PLC | 6.88% | 110,257 | $12.3M | Add +1.1% |
| BNTX Biontech SE-ADR | 6.23% | 93,583 | $11.1M | Reduce -29.3% |
| SNY Sanofi-ADR | 4.85% | 150,205 | $8.7M | Reduce -2.4% |
| ALKS Alkermes PLC | 3.94% | 251,495 | $7.0M | Reduce -2.4% |
| INDV Indivior Ltd. | 3.83% | 701,873 | $6.8M | New |
| VNDA Vanda Pharmaceuticals Inc. | 1.09% | 414,684 | $1.9M | Reduce -37.4% |
| REGN Regeneron Pharmaceuticals | 0.21% | 353 | $371K | Reduce -95.5% |
| MURA Mural Oncology PLC | 0.13% | 75,868 | $237K | Add +1.1% |
Portfolio Sells Q2 2024 → Q3 2024
| TARO Taro Pharmaceutical Indus | Sold out | 0.00% | −12.83 |
| REGN Regeneron Pharmaceuticals | Reduce -95.5% | 0.21% | −3.58 |
| BIIB Biogen Inc. | Reduce -8.3% | 12.33% | −0.85 |
| VNDA Vanda Pharmaceuticals Inc. | Reduce -37.4% | 1.09% | −0.63 |
| ALKS Alkermes PLC | Reduce -2.4% | 3.94% | +1.09 |
| EXEL Exelixis Inc. | Reduce -23.6% | 18.64% | +1.33 |
| BNTX Biontech SE-ADR | Reduce -29.3% | 6.23% | +1.35 |
| SNY Sanofi-ADR | Reduce -2.4% | 4.85% | +1.42 |
| UTHR United Therapeutics Corp. | Reduce -15.1% | 20.15% | +2.86 |
| CAH Cardinal Health Inc. | Reduce -3.4% | 13.02% | +3.20 |
Portfolio Buys Q2 2024 → Q3 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $263.2M | ENTA, JAZZ, UTHR, BMRN, EXEL |
| Q1 2026 | 20 | $255.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q4 2025 | 18 | $283.1M | UTHR, ENTA, BMRN, JAZZ, EXEL |
| Q3 2025 | 17 | $234.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q2 2025 | 15 | $188.9M | UTHR, CAH, EXEL, JAZZ, ENTA |
| Q1 2025 | 14 | $180.9M | EXEL, UTHR, CAH, SUPN, JAZZ |
| Q4 2024Amended | 12 | $169.0M | UTHR, EXEL, CAH, BIIB, JAZZ |
| Q3 2024 | 13 | $178.5M | UTHR, EXEL, CAH, BIIB, ENTA |
| Q2 2024 | 13 | $217.8M | EXEL, UTHR, BIIB, TARO, CAH |
| Q1 2024 | 12 | $225.5M | EXEL, UTHR, BIIB, TARO, CAH |